{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:05:37Z","timestamp":1772294737978,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40262-023-01327-2","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T09:02:43Z","timestamp":1700125363000},"page":"13-26","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Preclinical Pharmacokinetic\/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review"],"prefix":"10.1007","volume":"63","author":[{"given":"Theresa","family":"Pecho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-5878","authenticated-orcid":false,"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"1327_CR1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004404","author":"GD Brown","year":"2012","unstructured":"Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden Killers: human fungal infections. Sci Transl Med. 2012. https:\/\/doi.org\/10.1126\/scitranslmed.3004404.","journal-title":"Sci Transl Med"},{"issue":"9390","key":"1327_CR2","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","volume":"362","author":"DW Denning","year":"2003","unstructured":"Denning DW. Echinocandin antifungal drugs. The Lancet. 2003;362(9390):1142\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(03)14472-8.","journal-title":"The Lancet"},{"key":"1327_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1046\/j.1469-0691.2000.00006.x","volume":"6","author":"B de Pauw","year":"2000","unstructured":"de Pauw B. Is there a need for new antifungal agents? Clin Microbiol Infect. 2000;6:23\u20138. https:\/\/doi.org\/10.1046\/j.1469-0691.2000.00006.x.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"1327_CR4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1128\/CMR.9.4.499","volume":"9","author":"SK Fridkin","year":"1996","unstructured":"Fridkin SK, Jarvis WR. \u2018Epidemiology of nosocomial fungal infections. Clin Microbiol Rev. 1996;9(4):499\u2013511.","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"1327_CR5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0966-842X(97)01108-6","volume":"5","author":"ME Klepser","year":"1997","unstructured":"Klepser ME, Ernst EJ, Pfaller MA. Update on antifungal resistance. Trends Microbiol. 1997;5(9):372\u20135. https:\/\/doi.org\/10.1016\/S0966-842X(97)01108-6.","journal-title":"Trends Microbiol"},{"issue":"Supplement_3","key":"1327_CR6","doi-asserted-by":"publisher","first-page":"S328","DOI":"10.1093\/mmy\/myz012","volume":"57","author":"R Van Daele","year":"2019","unstructured":"Van Daele R, et al. Antifungal drugs: what brings the future? Med Mycol. 2019;57(Supplement_3):S328\u201343. https:\/\/doi.org\/10.1093\/mmy\/myz012.","journal-title":"Med Mycol"},{"issue":"12","key":"1327_CR7","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1016\/S1473-3099(17)30316-X","volume":"17","author":"DS Perlin","year":"2017","unstructured":"Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17(12):e383\u201392. https:\/\/doi.org\/10.1016\/S1473-3099(17)30316-X.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1327_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1086\/320876","volume":"33","author":"JH Rex","year":"2001","unstructured":"Rex JH, et al. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis. 2001;33(1):95\u2013106. https:\/\/doi.org\/10.1086\/320876.","journal-title":"Clin Infect Dis"},{"key":"1327_CR9","unstructured":"\u2018Authorisation of medicines | European Medicines Agency\u2019. https:\/\/www.ema.europa.eu\/en\/about-us\/what-we-do\/authorisation-medicines. Accessed 3 Mar 2023"},{"issue":"1","key":"1327_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1128\/AAC.42.1.161","volume":"42","author":"F Marco","year":"1998","unstructured":"Marco F, Pfaller MA, Messer S, Jones RN. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother. 1998;42(1):161\u20133.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1327_CR11","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1128\/AAC.41.4.841","volume":"41","author":"SA Radford","year":"1997","unstructured":"Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother. 1997;41(4):841\u20133. https:\/\/doi.org\/10.1128\/AAC.41.4.841.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1327_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/jac\/45.5.673","volume":"45","author":"PH Chandrasekar","year":"2000","unstructured":"Chandrasekar PH. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J Antimicrob Chemother. 2000;45(5):673\u20136. https:\/\/doi.org\/10.1093\/jac\/45.5.673.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"1327_CR13","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1128\/AAC.47.10.3165-3169.2003","volume":"47","author":"D Andes","year":"2003","unstructured":"Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 2003;47(10):3165\u20139. https:\/\/doi.org\/10.1128\/AAC.47.10.3165-3169.2003.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1327_CR14","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/14787210.2016.1207526","volume":"14","author":"KM Job","year":"2016","unstructured":"Job KM, et al. Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections. Expert Rev Anti Infect Ther. 2016;14(8):731\u201346. https:\/\/doi.org\/10.1080\/14787210.2016.1207526.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"5","key":"1327_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1086\/324620","volume":"34","author":"DW Denning","year":"2002","unstructured":"Denning DW, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34(5):563\u201371. https:\/\/doi.org\/10.1086\/324620.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1327_CR16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht R, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408\u201315. https:\/\/doi.org\/10.1056\/NEJMoa020191.","journal-title":"N Engl J Med"},{"issue":"2","key":"1327_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0924-8579(01)00363-6","volume":"18","author":"K Uchida","year":"2001","unstructured":"Uchida K, Yokota N, Yamaguchi H. In vitro antifungal activity of posaconazole against various pathogenic fungi. Int J Antimicrob Agents. 2001;18(2):167\u201372. https:\/\/doi.org\/10.1016\/S0924-8579(01)00363-6.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"1327_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1128\/AAC.48.1.137-142.2004","volume":"48","author":"D Andes","year":"2004","unstructured":"Andes D, et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother. 2004;48(1):137\u201342. https:\/\/doi.org\/10.1128\/AAC.48.1.137-142.2004.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1327_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1086\/508774","volume":"44","author":"TJ Walsh","year":"2007","unstructured":"Walsh TJ, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44(1):2\u201312. https:\/\/doi.org\/10.1086\/508774.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1327_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/jac\/dki399","volume":"57","author":"PA Warn","year":"2006","unstructured":"Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother. 2006;57(1):135\u20138. https:\/\/doi.org\/10.1093\/jac\/dki399.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"1327_CR21","doi-asserted-by":"publisher","first-page":"7735","DOI":"10.1128\/AAC.01919-15","volume":"59","author":"MC Arendrup","year":"2015","unstructured":"Arendrup MC, Jensen RH, Meletiadis J. In vitro activity of isavuconazole and comparators against clinical isolates of the mucorales order. Antimicrob Agents Chemother. 2015;59(12):7735\u201342. https:\/\/doi.org\/10.1128\/AAC.01919-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1327_CR22","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1128\/AAC.04907-14","volume":"59","author":"S Seyedmousavi","year":"2015","unstructured":"Seyedmousavi S, Br\u00fcggemann RJM, Meis JF, Melchers WJG, Verweij PE, Mouton JW. Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. Antimicrob Agents Chemother. 2015;59(5):2855\u201366. https:\/\/doi.org\/10.1128\/AAC.04907-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1327_CR23","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1128\/AAC.01355-13","volume":"57","author":"AJ Lepak","year":"2013","unstructured":"Lepak AJ, Marchillo K, VanHecker J, Andes DR. Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary Aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother. 2013;57(12):6284\u20139. https:\/\/doi.org\/10.1128\/AAC.01355-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1327_CR24","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1128\/AAC.04586-14","volume":"59","author":"J Viljoen","year":"2015","unstructured":"Viljoen J, Azie N, Schmitt-Hoffmann A-H, Ghannoum M. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. Antimicrob Agents Chemother. 2015;59(3):1671\u20139. https:\/\/doi.org\/10.1128\/AAC.04586-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10020","key":"1327_CR25","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. The Lancet. 2016;387(10020):760\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(15)01159-9.","journal-title":"The Lancet"},{"issue":"7","key":"1327_CR26","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","volume":"16","author":"FM Marty","year":"2016","unstructured":"Marty FM, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828\u201337. https:\/\/doi.org\/10.1016\/S1473-3099(16)00071-2.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"1327_CR27","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1128\/AAC.41.7.1612","volume":"41","author":"JA Vazquez","year":"1997","unstructured":"Vazquez JA, Lynch M, Boikov D, Sobel JD. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother. 1997;41(7):1612\u20134. https:\/\/doi.org\/10.1128\/AAC.41.7.1612.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1327_CR28","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1128\/AAC.41.8.1835","volume":"41","author":"M Del Poeta","year":"1997","unstructured":"Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother. 1997;41(8):1835\u20136. https:\/\/doi.org\/10.1128\/AAC.41.8.1835.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1327_CR29","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1128\/AAC.44.9.2310-2318.2000","volume":"44","author":"GK Abruzzo","year":"2000","unstructured":"Abruzzo GK, et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother. 2000;44(9):2310\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1327_CR30","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1128\/AAC.45.2.596-600.2001","volume":"45","author":"AH Groll","year":"2001","unstructured":"Groll AH, et al. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob Agents Chemother. 2001;45(2):596. https:\/\/doi.org\/10.1128\/AAC.45.2.596-600.2001.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1327_CR31","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1128\/AAC.49.12.5058-5068.2005","volume":"49","author":"A Louie","year":"2005","unstructured":"Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother. 2005;49(12):5058\u201368. https:\/\/doi.org\/10.1128\/AAC.49.12.5058-5068.2005.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1327_CR32","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1086\/424465","volume":"190","author":"NP Wiederhold","year":"2004","unstructured":"Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis. 2004;190(8):1464\u201371. https:\/\/doi.org\/10.1086\/424465.","journal-title":"J Infect Dis"},{"issue":"9","key":"1327_CR33","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1086\/323401","volume":"33","author":"A Villanueva","year":"2001","unstructured":"Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2001;33(9):1529\u201335. https:\/\/doi.org\/10.1086\/323401.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"2","key":"1327_CR34","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1128\/AAC.46.2.451-457.2002","volume":"46","author":"EG Arathoon","year":"2002","unstructured":"Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin b for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother. 2002;46(2):451\u20137. https:\/\/doi.org\/10.1128\/AAC.46.2.451-457.2002.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1327_CR35","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.1128\/JCM.43.11.5425-5427.2005","volume":"43","author":"MA Pfaller","year":"2005","unstructured":"Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol. 2005;43(11):5425\u20137. https:\/\/doi.org\/10.1128\/JCM.43.11.5425-5427.2005.","journal-title":"J Clin Microbiol"},{"issue":"11","key":"1327_CR36","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1128\/AAC.00507-06","volume":"50","author":"T Gumbo","year":"2006","unstructured":"Gumbo T, et al. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother. 2006;50(11):3695\u2013700. https:\/\/doi.org\/10.1128\/AAC.00507-06.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1327_CR37","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1128\/AAC.01061-07","volume":"52","author":"D Andes","year":"2008","unstructured":"Andes D, et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2008;52(2):539\u201350. https:\/\/doi.org\/10.1128\/AAC.01061-07.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1327_CR38","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1128\/AAC.48.6.2021-2024.2004","volume":"48","author":"DS Krause","year":"2004","unstructured":"Krause DS, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother. 2004;48(6):2021\u20134. https:\/\/doi.org\/10.1128\/AAC.48.6.2021-2024.2004.","journal-title":"Antimicrob Agents Chemother"},{"issue":"24","key":"1327_CR39","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1056\/NEJMoa066906","volume":"356","author":"AC Reboli","year":"2007","unstructured":"Reboli AC, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356(24):2472\u201382. https:\/\/doi.org\/10.1056\/NEJMoa066906.","journal-title":"N Engl J Med"},{"key":"1327_CR40","unstructured":"\u2018In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi-PMC\u2019. [Online]. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC89628\/. Accessed 8 Feb 2023"},{"issue":"10","key":"1327_CR41","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1128\/AAC.00478-08","volume":"52","author":"DR Andes","year":"2008","unstructured":"Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmueller J. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2008;52(10):3497\u2013503. https:\/\/doi.org\/10.1128\/AAC.00478-08.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1327_CR42","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1086\/423377","volume":"39","author":"N De Wet","year":"2004","unstructured":"De Wet N, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. 2004;39(6):842\u20139. https:\/\/doi.org\/10.1086\/423377.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1327_CR43","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/j.1365-2036.2005.02427.x","volume":"21","author":"NTE De Wet","year":"2005","unstructured":"De Wet NTE, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther. 2005;21(7):899\u2013907. https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02427.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"1327_CR44","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1086\/422312","volume":"39","author":"J-AH van Burik","year":"2004","unstructured":"van Burik J-AH, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407\u201316. https:\/\/doi.org\/10.1086\/422312.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1327_CR45","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/antibiotics11080986","volume":"11","author":"LC Pereira","year":"2022","unstructured":"Pereira LC, de F\u00e1tima MA, Santos VV, Brand\u00e3o CM, Alves IA, Azeredo FJ. Pharmacokinetic\/pharmacodynamic modeling and application in antibacterial and antifungal pharmacotherapy: a narrative review. Antibiotics. 2022;11(8):986. https:\/\/doi.org\/10.3390\/antibiotics11080986.","journal-title":"Antibiotics"},{"key":"1327_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.888079","author":"ME Palmer","year":"2022","unstructured":"Palmer ME, Andrews LJ, Abbey TC, Dahlquist AE, Wenzler E. The importance of pharmacokinetics and pharmacodynamics in antimicrobial drug development and their influence on the success of agents developed to combat resistant gram negative pathogens: a review. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.888079.","journal-title":"Front Pharmacol"},{"issue":"9","key":"1327_CR47","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s40262-020-00892-0","volume":"59","author":"A Jorda","year":"2020","unstructured":"Jorda A, Zeitlinger M. Preclinical pharmacokinetic\/pharmacodynamic studies and clinical trials in the drug development process of EMA-approved antibacterial agents: a review. Clin Pharmacokinet. 2020;59(9):1071\u201384. https:\/\/doi.org\/10.1007\/s40262-020-00892-0.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1327_CR48","doi-asserted-by":"publisher","first-page":"ofaa016","DOI":"10.1093\/ofid\/ofaa016","volume":"7","author":"AM Rauseo","year":"2020","unstructured":"Rauseo AM, Coler-Reilly A, Larson L, Spec A. Hope on the Horizon: novel fungal treatments in development. Open Forum Infect Dis. 2020;7(2):ofaa016. https:\/\/doi.org\/10.1093\/ofid\/ofaa016.","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"1327_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.546","volume":"7","author":"L Miesel","year":"2019","unstructured":"Miesel L, Lin K, Ong V. Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: insights on the PK\/PD pharmacometrics of rezafungin efficacy. Pharmacol Res Perspect. 2019;7(6): e00546. https:\/\/doi.org\/10.1002\/prp2.546.","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"1327_CR50","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1128\/AAC.04445-14","volume":"59","author":"AJ Lepak","year":"2015","unstructured":"Lepak AJ, Marchillo K, Andes DR. Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015;59(2):1265\u201372. https:\/\/doi.org\/10.1128\/AAC.04445-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1327_CR51","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.1128\/AAC.00185-15","volume":"59","author":"EP Garvey","year":"2015","unstructured":"Garvey EP, Hoekstra WJ, Schotzinger RJ, Sobel JD, Lilly EA, Fidel PL. Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother. 2015;59(9):5567\u201373. https:\/\/doi.org\/10.1128\/AAC.00185-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"1327_CR52","unstructured":"Guideline on the clinical evaluation of antifungal agents for the treatment and prophylaxis of invasive fungal disease, 22 April 2010, CHMP\/EWP\/1343\/01 Rev. 1, Committee for Medicinal Products for Human Use (CHMP)"},{"key":"1327_CR53","unstructured":"Points to consider on the clinical evaluation of new agents for invasive fungal infections, 22 May 2003, CPMP\/EWP\/1343\/01, Committee for Proprietary Medicinal Products (CPMP)"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01327-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01327-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01327-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T07:32:49Z","timestamp":1705044769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01327-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1327"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01327-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"assertion":[{"value":"30 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Medical University of Vienna.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Theresa Pecho and Markus Zeitlinger do not have any conflict of interest directly relevant to the content of this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Both authors contributed to the concept and writing of the paper.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}